EW

SEC source: 0001225208-23-007511 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 222,453.7137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

SEC source: 0001225208-23-007434 · doc4.xml · derivative · entry 4

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,000

Underlying: Common Stock · 5,000 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-007434 · doc4.xml · nonDerivative · entry 3

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,813.571

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.

SEC source: 0001225208-23-007434 · doc4.xml · nonDerivative · entry 2

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,813.571

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.

SEC source: 0001225208-23-007394 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,583.7785

SEC source: 0001225208-23-007434 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,813.571

SEC source: 0001225208-23-007306 · doc4.xml · derivative · entry 6

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 293,500

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,251.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $90.09 to $91.09 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,979.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $91.10 to $91.50 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,601.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

SEC source: 0001225208-23-007036 · doc4.xml · derivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,545

Underlying: Common Stock · 7,255 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-007036 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,248

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023.

SEC source: 0001225208-23-007036 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023.

SEC source: 0001225208-23-006824 · doc4.xml · derivative · entry 5

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,500

Underlying: Common Stock · 3,500 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-006824 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,502.6931

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023.

SEC source: 0001225208-23-006824 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,002.6931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023.

SEC source: 0001225208-23-006823 · doc4.xml · derivative · entry 5

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,719

Underlying: Common Stock · 8,660 shares

Expires 2025-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-006823 · doc4.xml · nonDerivative · entry 3

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,793.7137

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $89.47 to $90.46 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-006823 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 219,603.7137

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $90.49 to $90.97 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-006823 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 222,453.7137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

SEC source: 0001225208-23-006806 · doc4.xml · derivative · entry 3

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 5,000 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-006806 · doc4.xml · nonDerivative · entry 2

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,055.7795

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $85.75 to $86.23 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-006806 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,055.7795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.

SEC source: 0001225208-23-006458 · doc4.xml · derivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 322,850

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-006458 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,209.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $84.025 to $85.020 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-006458 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,863.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $85.030 to $85.130 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-006458 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,259.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $83.000 to $84.000 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-006458 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,559.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

SEC source: 0001225208-23-006208 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,379

Underlying: Common Stock · 6,421 shares

Expires 2025-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-006208 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,793.7137

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

SEC source: 0001225208-23-006208 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,214.7137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

SEC source: 0001225208-23-006019 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 266,318

SEC source: 0001225208-23-006019 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,248

SEC source: 0001225208-23-005911 · doc4.xml · nonDerivative · entry 1

VALERIANI NICHOLAS J · CIK 0001263149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,914

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005912 · doc4.xml · derivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,589

Underlying: Common Stock · 3,589 shares

Expires 2030-05-11

F2 · derivative.exercise_date: These options were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-23-005912 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,209.82

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005910 · doc4.xml · nonDerivative · entry 1

Sequeira Ramona · CIK 0001811081 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,103

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005909 · doc4.xml · nonDerivative · entry 1

Marsh Martha H. · CIK 0001500281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,880

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005908 · doc4.xml · nonDerivative · entry 2

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,318

F2 · shares: This restricted stock was granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005908 · doc4.xml · nonDerivative · entry 1

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,420

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005907 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,718

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005906 · doc4.xml · nonDerivative · entry 2

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,701

F2 · shares: This restricted stock was granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005906 · doc4.xml · nonDerivative · entry 1

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,803

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005905 · doc4.xml · derivative · entry 2

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,795

Underlying: Common Stock · 1,795 shares

Expires 2030-05-11

F2 · derivative.exercise_date: These options were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-23-005905 · doc4.xml · nonDerivative · entry 1

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,283

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005920 · doc4.xml · derivative · entry 3

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,540

Underlying: Common Stock · 5,540 shares

Expires 2030-05-10

F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-23-005920 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,035.7904

F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-23-005919 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,725

Underlying: Common Stock · 9,725 shares

Expires not disclosed

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-23-005919 · doc4.xml · derivative · entry 3

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,700

Underlying: Common Stock · 65,700 shares

Expires 2030-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-23-005919 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,793.7137

F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2 · balance_after: Reflects shares transferred to the reporting person's ex-spouse pursuant to a divorce judgement. The securities owned by the ex-spouse are not beneficially owned by the reporting person.